4-methoxybenzyl 4-(4-(benzyloxy)-3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | 1431221-63-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methoxybenzyl 4-(4-(benzyloxy)-3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
• 英文别名: (4-methoxyphenyl)methyl 4-(3-methoxy-4-phenylmethoxyphenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate
• CAS: 1431221-63-4
• 化学式: C₂₈H₂₈N₂O₆
• 分子量: 488.54
• InChiKey: XVIFPTBPCBLOLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-甲氧基苄醇 在 potassium acetate 、 ytterbium(III) triflate 作用下， 以 neat (no solvent) 为溶剂， 反应 1.08h， 生成 4-methoxybenzyl 4-(4-(benzyloxy)-3-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  参考文献：
  名称：

  3,4-二氢嘧啶-2（1H）-酮作为碘化物钠转运抑制剂的合成与评价

  摘要：

  碘化钠共转运蛋白（NIS）负责碘在甲状腺中的积累。这种运输过程涉及许多甲状腺功能障碍，是暴露于放射性碘物种时人为污染的基础。4-芳基-3,4-二氢嘧啶-2（1 H）-一种通过高通量筛选最近发现的化合物是第一种NIS抑制剂。本文描述了115个在嘧啶酮核心上五个关键位置具有结构修饰的衍生物的合成和评估。这项研究为这类新型抑制剂提供了广泛的构效关系，将为进一步开发具有体内功效和足够药代动力学特性的化合物奠定基础。另外，SAR调查提供了更有效的化合物，其表现出的IC 50为3.2的n值中号在大鼠甲状腺细胞系（FRTL5）。

  DOI：

  10.1002/cmdc.201200417

文献信息

• Identification of New Nonsteroidal RORα Ligands; Related Structure–Activity Relationships and Docking Studies
  作者：Mathieu Dubernet、Nicolas Duguet、Lionel Colliandre、Christophe Berini、Stéphane Helleboid、Marilyne Bourotte、Matthieu Daillet、Lucie Maingot、Sébastien Daix、Jean-François Delhomel、Luc Morin-Allory、Sylvain Routier、Robert Walczak

  DOI：10.1021/ml300471d

  日期：2013.6.13

  A high throughput screen was developed to identify novel, nonsteroidal ROR alpha agonists. Among the validated hit compounds, the 4-(-(benzyloxy)phenyl)-5-carbonyl-2-oxo-1,2,3,4-tetrahydropyrimidine scaffold was the most prominent Among the numerous analogues tested, compounds 8 and 9 showed the highest activity. Key structure-activity relationships (SAR) were established, where benzyl and urea moieties were both identified as very important elements to maintain the activity. Most notably, the SAR were consistent with the binding mode of the compound 8 (S-isomer) in the ROR alpha docking model that was developed in this program. As predicted by the model, the urea moiety is engaged in the formation of key hydrogen bonds with the backbone of Tyr380 and Asp382. The benzyl group is located in a wide hydrophobic pocket. The structural relationships reported in this letter will help in further optimization of this compound series and will provide novel synthetic probes helpful for elucidation of complex ROR alpha physiopathology.